Tag: Imara

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Coronary/Structural Heart Regulatory by 0 comments

Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expression for targeted approach to a heterogeneous disease Study initiation planned for second quarter of 2022 BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) […]

Continue Reading →

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Financial by 0 comments

 Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 activator shown to reactivate fetal hemoglobin and reduce VOCs in preclinical models of sickle cell disease Building […]

Continue Reading →

Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Coronary/Structural Heart by 0 comments

Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara’s new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage […]

Continue Reading →